利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

85 条记录 (耗时 0.06 秒)

    Identification of Unique Binding Interactions Between Certain Antibodies and the Human B7.1 and B7.2 Co-Stimulatory Antigens
    72.
    发明申请
    Identification of Unique Binding Interactions Between Certain Antibodies and the Human B7.1 and B7.2 Co-Stimulatory Antigens 有权
    鉴定某些抗体与人B7.1和B7.2共刺激抗原之间的独特结合相互作用

    公开(公告)号：US20080038254A1

    公开(公告)日：2008-02-14

    申请号：US11464123

    申请日：2006-08-11

    申请人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    发明人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    IPC分类号： A61K39/395 ,  C07K16/18

    CPC分类号： C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    摘要翻译： 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。 阻断CD28和B7.1（CD80）之间的主要激活信号与这些抗体同时允许CTLA-4和B7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

    Anti-CD80 antibodies
    73.
    发明授权
    Anti-CD80 antibodies 有权
    抗CD80抗体

    公开(公告)号：US07323170B2

    公开(公告)日：2008-01-29

    申请号：US10986780

    申请日：2004-11-15

    申请人： Darrell R. Anderson ,  Peter Brams ,  Nabil Hanna ,  William S. Shestowsky ,  Cheryl Heard

    发明人： Darrell R. Anderson ,  Peter Brams ,  Nabil Hanna ,  William S. Shestowsky ,  Cheryl Heard

    IPC分类号： A61K39/395 ,  C07K16/28

    CPC分类号： C07K14/70532 ,  A61K38/00 ,  C07K16/2827

    摘要： The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention provides four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effective immunosuppressants. The invention further provides the complete DNA and amino acid sequences of the light and heavy chain of three PRIMATIZED® antibodies derived from those monkey monoclonal antibodies which bind B7.1 and possibly B7.2, PRIMATIZED® 7C10, PRIMATIZED® 7B6 and PRIMATIZED® 16C10. These PRIMATIZED® and monkey antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    摘要翻译： 本发明涉及通过筛选使用B7.1和/或B7.2免疫的猴子的B淋巴细胞获得的噬菌体展示文库或猴杂合杂交瘤来鉴定人B7.1和B7.2的猕猴抗体。 更具体地，本发明提供四种抑制B7：CD28途径的猴单克隆抗体7B6,16C10,7C10和20C9，从而起到有效的免疫抑制剂的作用。 本发明进一步提供来源于那些结合B7.1和可能B7.2，PRIMATIZED 7C10，PRIMATIZED（R）的猴单克隆抗体的三种PRIMATIZED（R）抗体的轻链和重链的完整DNA和氨基酸序列 ）7B6和PRICATIZED16C10。 这些PRIMATIZED和猴抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫疾病和预防器官移植排斥。

    CD80 specific antibodies
    74.
    发明授权
    CD80 specific antibodies 有权
    CD80特异性抗体

    公开(公告)号：US07192585B2

    公开(公告)日：2007-03-20

    申请号：US11139499

    申请日：2005-05-31

    申请人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    发明人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    IPC分类号： A61K39/395 ,  C07K16/28

    CPC分类号： C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (GD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    摘要翻译： 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（GD86），但是这些抗体中的两种，16C10和7C10，显着抑制IL-2的产生。 阻断CD28和B7.1（CD80）之间的主要激活信号与这些抗体同时允许CTLA-4和B7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

    Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
    75.
    发明授权
    Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 有权
    用不会抑制CD80与CTLA-4结合的抗CD80抗体治疗肠道炎症

    公开(公告)号：US07175847B1

    公开(公告)日：2007-02-13

    申请号：US09576424

    申请日：2000-05-22

    申请人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    发明人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    IPC分类号： A61K39/395 ,  C07K16/28

    CPC分类号： C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies, or B7.1-binding fragments thereof, may be used for the treatment of Crohn's disease.

    摘要翻译： 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。 阻断CD28和B7.1（CD80）之间的主要激活信号与这些抗体同时允许CTLA-4和B7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体或其B7.1结合片段可用于治疗克罗恩氏病。